Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 8/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.42 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3776044 | 0.88 | SLC2A1 (0.41) | SLC2A1KCNH2MTNR1BMTNR1ALMNA | |
| SCHEMBL4269291 | 0.84 | SLC2A1 (0.63) | SLC2A1KCNH2 | |
| SCHEMBL5256391 | 0.84 | SLC2A1 (0.63) | SLC2A1KCNH2 | |
| SCHEMBL5256396 | 0.84 | SLC2A1 (0.63) | SLC2A1KCNH2 | |
| SCHEMBL5264168 | 0.84 | MTNR1B (0.41) | SLC2A1KCNH2MTNR1BMTNR1A | |
| Hydrochloric Acid SCHEMBL5411589 | 0.83 | SLC2A1 (0.62) | SLC2A1KCNH2 | |
| SCHEMBL5266900 | 0.82 | SLC2A1 (0.40) | SLC2A1KCNH2MTNR1BMTNR1ACCR3 | |
| SCHEMBL3775540 | 0.82 | SLC2A1 (0.42) | SLC2A1KCNH2MTNR1BMTNR1ALMNA | |
| SCHEMBL3774752 | 0.81 | KCNH2 (0.49) | SLC2A1KCNH2MTNR1BMTNR1ACCR3 | |
| SCHEMBL3769272 | 0.81 | SLC2A1 (0.53) | SLC2A1KCNH2MTNR1BMTNR1ACCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2010-12-23 | — | — | US | disclosed |
| EP-1943222-A1 | ANTIBACTERIAL ACTIVE 5-CHINOLIN DERIVATIVE | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007042325-A1 | ANTIBACTERIAL ACTIVE 5-CHINOLIN DERIVATIVE | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | TOP2A, TOP1, TOP2B | SLC2A1 4605/4885KCNH2 3216/4885MTNR1B 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.